Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Hypertension ; 78(5): 1296-1309, 2021 11.
Article in English | MEDLINE | ID: mdl-34488433

ABSTRACT

IL-18 (interleukin-18) is elevated in hypertensive patients, but its contribution to high blood pressure and end-organ damage is unknown. We examined the role of IL-18 in the development of renal inflammation and injury in a mouse model of low-renin hypertension. Hypertension was induced in male C57BL6/J (WT) and IL-18−/− mice by uninephrectomy, deoxycorticosterone acetate (2.4 mg/d, s.c.) and 0.9% drinking saline (1K/DOCA/salt). Normotensive controls received uninephrectomy and placebo (1K/placebo). Blood pressure was measured via tail cuff or radiotelemetry. After 21 days, kidneys were harvested for (immuno)histochemical, quantitative-PCR and flow cytometric analyses of fibrosis, inflammation, and immune cell infiltration. 1K/DOCA/salt-treated WT mice developed hypertension, renal fibrosis, upregulation of proinflammatory genes, and accumulation of CD3+ T cells in the kidneys. They also displayed increased expression of IL-18 on tubular epithelial cells. IL-18−/− mice were profoundly protected from hypertension, renal fibrosis, and inflammation. Bone marrow transplantation between WT and IL-18−/− mice revealed that IL-18-deficiency in non-bone marrow-derived cells alone afforded equivalent protection against hypertension and renal injury as global IL-18 deficiency. IL-18 receptor subunits­interleukin-18 receptor 1 and IL-18R accessory protein­were upregulated in kidneys of 1K/DOCA/salt-treated WT mice and localized to T cells and tubular epithelial cells. T cells from kidneys of 1K/DOCA/salt-treated mice produced interferon-γ upon ex vivo stimulation with IL-18, whereas those from 1K/placebo mice did not. In conclusion, IL-18 production by tubular epithelial cells contributes to elevated blood pressure, renal inflammation, and fibrosis in 1K/DOCA/salt-treated mice, highlighting it as a promising therapeutic target for hypertension and kidney disease.


Subject(s)
Epithelial Cells/metabolism , Hypertension/physiopathology , Inflammation/metabolism , Interleukin-18/metabolism , Kidney Diseases/metabolism , Albuminuria/chemically induced , Albuminuria/genetics , Albuminuria/metabolism , Animals , Blood Pressure/genetics , Blood Pressure/physiology , Desoxycorticosterone Acetate , Hypertension/chemically induced , Hypertension/genetics , Inflammation/genetics , Interleukin-18/genetics , Kidney/metabolism , Kidney/pathology , Kidney Diseases/genetics , Kidney Tubules/cytology , Male , Mice, Inbred C57BL , Mice, Knockout , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
2.
Cardiovasc Res ; 115(4): 776-787, 2019 03 15.
Article in English | MEDLINE | ID: mdl-30357309

ABSTRACT

AIMS: Renal inflammation, leading to fibrosis and impaired function is a major contributor to the development of hypertension. The NLRP3 inflammasome mediates inflammation in several chronic diseases by processing the cytokines pro-interleukin (IL)-1ß and pro-IL-18. In this study, we investigated whether MCC950, a recently-identified inhibitor of NLRP3 activity, reduces blood pressure (BP), renal inflammation, fibrosis and dysfunction in mice with established hypertension. METHODS AND RESULTS: C57BL6/J mice were made hypertensive by uninephrectomy and treatment with deoxycorticosterone acetate (2.4 mg/day, s.c.) and 0.9% NaCl in the drinking water (1K/DOCA/salt). Normotensive controls were uninephrectomized and received normal drinking water. Ten days later, mice were treated with MCC950 (10 mg/kg/day, s.c.) or vehicle (saline, s.c.) for up to 25 days. BP was monitored by tail-cuff or radiotelemetry; renal function by biochemical analysis of 24-h urine collections; and kidney inflammation/pathology was assessed by real-time PCR for inflammatory gene expression, flow cytometry for leucocyte influx, and Picrosirius red histology for collagen. Over the 10 days post-surgery, 1K/DOCA/salt-treated mice became hypertensive, developed impaired renal function, and displayed elevated renal levels of inflammatory markers, collagen and immune cells. MCC950 treatment from day 10 attenuated 1K/DOCA/salt-induced increases in renal expression of inflammasome subunits (NLRP3, ASC, pro-caspase-1) and inflammatory/injury markers (pro-IL-18, pro-IL-1ß, IL-17A, TNF-α, osteopontin, ICAM-1, VCAM-1, CCL2, vimentin), each by 25-40%. MCC950 reduced interstitial collagen and accumulation of certain leucocyte subsets in kidneys of 1K/DOCA/salt-treated mice, including CD206+ (M2-like) macrophages and interferon-gamma-producing T cells. Finally, MCC950 partially reversed 1K/DOCA/salt-induced elevations in BP, urine output, osmolality, [Na+], and albuminuria (each by 20-25%). None of the above parameters were altered by MCC950 in normotensive mice. CONCLUSION: MCC950 was effective at reducing BP and limiting renal inflammation, fibrosis and dysfunction in mice with established hypertension. This study provides proof-of-concept that pharmacological inhibition of the NLRP3 inflammasome is a viable anti-hypertensive strategy.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antihypertensive Agents/pharmacology , Blood Pressure/drug effects , Furans/pharmacology , Hypertension/prevention & control , Kidney/drug effects , NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors , Sodium Chloride, Dietary , Sulfonamides/pharmacology , Albuminuria/etiology , Albuminuria/metabolism , Albuminuria/physiopathology , Albuminuria/prevention & control , Animals , Chemotaxis, Leukocyte/drug effects , Collagen/metabolism , Desoxycorticosterone Acetate , Disease Models, Animal , Fibrosis , Heterocyclic Compounds, 4 or More Rings , Hypertension/etiology , Hypertension/metabolism , Hypertension/physiopathology , Indenes , Inflammation Mediators/metabolism , Kidney/metabolism , Kidney/pathology , Kidney/physiopathology , Macrophages/drug effects , Macrophages/metabolism , Male , Mice, Inbred C57BL , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Nephrectomy , Signal Transduction , Sulfones , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/metabolism
3.
Clin Exp Pharmacol Physiol ; 37(9): 926-32, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20497419

ABSTRACT

1. Previous work indicates that agonists of ghrelin receptors can act within the spinal cord to stimulate autonomic outputs to the colorectum and to blood vessels. Because of the close relationship between colorectal and urinary bladder control, we have investigated whether ghrelin receptor agonists also stimulate spinal centres that influence the bladder. 2. The ghrelin receptor agonist capromorelin (10 mg/kg), injected intravenously in anaesthetized male rats, disrupted the ongoing cycle of micturition reflexes and caused phasic oscillations in pressure that averaged approximately 20 mmHg. Fluid output from the bladder was diminished. The effects of capromorelin were inhibited by hexamethonium (10 mg/kg bolus followed by 4 mg/kg per h infusion, i.v.) and were further reduced by atropine (5 mg/kg bolus followed by 2.5 mg/kg per h infusion, i.v.). Capromorelin (250 microg) injected directly into the spinal cord at the lumbosacral level also increased contractile activity of the bladder. However, capromorelin, up to 0.1 mmol/L, had no effect on the tension of isolated muscle strips from the bladder. Effects of intravenous capromorelin (10 mg/kg) on bladder pressure were still observed after the descending pathways in the spinal cord were disrupted at the thoracic level. 3. In situ hybridization studies revealed ghrelin receptor gene expression in neurons of the autonomic intermediolateral (IML) cell columns. Following a series of micturition reflexes elicited by infusion of saline into the bladder, the immediate early gene product c-Fos was observed in neurons of the lumbosacral IML and approximately 20% of these also expressed ghrelin receptor gene transcripts. 4. It is concluded that ghrelin receptors are expressed by lumbosacral autonomic preganglionic neurons of the micturition reflex pathways and that ghrelin receptor agonists stimulate these neurons.


Subject(s)
Autonomic Fibers, Preganglionic/physiology , Receptors, Ghrelin/metabolism , Urination/physiology , Animals , Gene Expression , Male , Piperidines/pharmacology , Proto-Oncogene Proteins c-fos/isolation & purification , Proto-Oncogene Proteins c-fos/metabolism , Pyrazoles/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Ghrelin/agonists , Receptors, Ghrelin/genetics , Reflex , Spinal Cord/drug effects , Spinal Cord/physiology , Spinal Cord Injuries , Urinary Bladder/drug effects , Urinary Bladder/immunology , Urinary Bladder/physiology
4.
J Physiol ; 576(Pt 1): 329-38, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16873401

ABSTRACT

Previous studies have failed to reveal an effect of the gastrointestinal peptide hormone ghrelin on colonic motility. In the present work, ghrelin was applied into the lumbo-sacral spinal cord in the region of defecation control centres, and a synthetic ghrelin receptor agonist, CP464709, which crosses the blood-brain barrier, was applied intravenously or into the lumbo-sacral cord. Both ghrelin and CP464709 elicited propulsive contractions and emptying of the colon in anaesthetized rats. In conscious rats, subcutaneous CP464709 caused fecal expulsion. The sites of action and nerve pathways involved in the stimulation of the colon by ghrelin receptor activation were investigated in anaesthetized rats. Intrathecal application of CP464709 at L6-S1, but not application at ponto-medullary levels or to the thoracic spinal cord, elicited propulsive contractions. The stimulation evoked by intravenous CP464709 was prevented if the pelvic nerve outflows were severed, but not if the spinal cord was cut rostral to the defecation centre at L6-S3. The response was also blocked by hexamethonium. When ghrelin, applied intrathecally, was used to desensitize its receptors, the effect of intravenous CP464709 was blocked. CP464709 did not affect small intestine motility or the amplitudes of visceromotor reflexes caused by colorectal distension. It is concluded that activation of ghrelin receptors in the lumbo-sacral spinal cord triggers co-ordinated propulsive contractions that empty the colo-rectum. The pathways through which these responses are generated pass out of the spinal cord via the pelvic nerves and cause propulsive contractions through activation of enteric neurons.


Subject(s)
Colon/physiology , Gastrointestinal Motility/physiology , Receptors, G-Protein-Coupled/physiology , Spinal Cord/physiology , Animals , Colon/innervation , Defecation/drug effects , Defecation/physiology , Evoked Potentials/drug effects , Evoked Potentials/physiology , Ganglionic Blockers/pharmacology , Gastrointestinal Motility/drug effects , Ghrelin , Hexamethonium/pharmacology , Male , Motor Neurons/drug effects , Motor Neurons/physiology , Peptide Hormones/physiology , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/agonists , Receptors, Ghrelin
5.
Stroke ; 33(12): 2972-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12468799

ABSTRACT

BACKGROUND AND PURPOSE: The contribution of endothelium-derived hyperpolarizing factor (EDHF) to ATP-mediated dilations is significantly attenuated in the rat middle cerebral artery of intact and estrogen-treated ovariectomized (OVX) females compared with males and vehicle-treated OVX females. Since an increase in endothelial calcium appears to be a critical prerequisite in the EDHF response, we tested the hypothesis that endothelial cell intracellular calcium ([Ca(2+)](i)) fails to reach sufficient levels to elicit robust EDHF-mediated dilations in females and that this effect is mediated by estrogen. METHODS: Vascular diameter and [Ca(2+)](i) were measured concomitantly in perfused middle cerebral artery segments with the use of videomicroscopy and fura 2 fluorescence, respectively. RESULTS: In the presence of N(G)-nitro-L-arginine methyl ester and indomethacin, the dilation to 10(-5) mol/L ATP was significantly reduced (P<0.05) in intact females (42+/-8%; n=6) and estrogen-treated OVX females (25+/-6%; n=9) compared with intact males (89+/-5%; n=6) and vehicle-treated OVX females (92+/-2%; n=7). Contrary to our initial hypothesis, endothelial cell [Ca(2+)](i) increased to comparable levels in intact females (461+/-116 nmol/L), estrogen-treated OVX females (417+/-50 nmol/L), intact males (421+/-77 nmol/L), and vehicle-treated OVX females (530+/-92 nmol/L). In response to luminal ATP (10(-5) mol/L), smooth muscle cell [Ca(2+)](i) decreased to a greater degree in males (37+/-4%; n=8) compared with females (21+/-5%; n=7) and in vehicle-treated OVX females (18+/-7%; n=7) compared with estrogen-treated OVX females (3+/-5%; n=9). CONCLUSIONS: Our data suggest that loss of a factor coupling EDHF to reduction of ionized smooth muscle cell [Ca(2+)](i) accounts for the attenuated EDHF-mediated dilations in the female middle cerebral artery.


Subject(s)
Biological Factors/metabolism , Calcium/metabolism , Middle Cerebral Artery/physiology , Vasodilation/physiology , Animals , Biological Factors/pharmacology , Drug Implants/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Estradiol/pharmacology , Female , Fluorescent Dyes , In Vitro Techniques , Male , Microscopy, Video , Middle Cerebral Artery/drug effects , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Ovariectomy , Rats , Rats, Long-Evans , Sex Factors , Vascular Patency/drug effects , Vascular Patency/physiology , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...